Product Name :
AG-825
Description:
AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development.
CAS:
149092-50-2
Molecular Weight:
397.47
Formula:
C19H15N3O3S2
Chemical Name:
(2E)-3-{3-[(1, 3-benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoprop-2-enamide
Smiles :
COC1=CC(=CC(CSC2=NC3=CC=CC=C3S2)=C1O)/C=C(\C#N)/C(N)=O
InChiKey:
KXDONFLNGBQLTN-WUXMJOGZSA-N
InChi :
InChI=1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)/b12-6+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development.|Product information|CAS Number: 149092-50-2|Molecular Weight: 397.47|Formula: C19H15N3O3S2|Synonym:|Tyrphostin AG-825|Chemical Name: (2E)-3-{3-[(1, 3-benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoprop-2-enamide|Smiles: COC1=CC(=CC(CSC2=NC3=CC=CC=C3S2)=C1O)/C=C(\C#N)/C(N)=O|InChiKey: KXDONFLNGBQLTN-WUXMJOGZSA-N|InChi: InChI=1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)/b12-6+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (628.98 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Lanosterol} MedChemExpress|{Lanosterol} Metabolic Enzyme/Protease|{Lanosterol} Protocol|{Lanosterol} References|{Lanosterol} manufacturer|{Lanosterol} Cancer} |Shelf Life: ≥360 days if stored properly.{{Carboxy-PTIO} MedChemExpress|{Carboxy-PTIO} Immunology/Inflammation|{Carboxy-PTIO} Epigenetics|{Carboxy-PTIO} Technical Information|{Carboxy-PTIO} Description|{Carboxy-PTIO} custom synthesis} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:33325776 |Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Wolfson E, et al. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death Dis. 2018 Jan 19;9(2):47.Gazit A, et al. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64.He H, et al. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001 May-Jun;7(3):191-202.Products are for research use only. Not for human use.|
